Kieran Ryan: Got it. Thanks, and then just a quick follow-up, the prior question was kind of talking about the strong demand that, hospitals and some providers you’re seeing now. I was just wondering, does the top line guide in diagnostics at all contemplate a normalization in kind of broader utilization? Or are you just really not seeing anything outside of what you’d expect at this point? Thanks.
Adam Schechter: Yes. I would say that we’re seeing what we would expect at this point is slightly higher, we give a range because there’s a range of different things that may or may not occur. But overall, we think that the environment is healthy.
Glenn Eisenberg: Yes. When you look at the — also, Pito, I guess, our implied guidance, so you’re looking at a stronger top line growth than what we did in the first quarter with our guidance, but that’s just really driven off of COVID becoming less of an issue. It was a bigger issue in the first quarter decline year-on-year, plus that’s where we had the adverse impact from weather. So really when you adjust for that, as Adam’s commented, the demand that we’re seeing, which is came in a little bit stronger than we expected. We expect that to be similar demand going forward throughout the rest of the year.
Operator: Thank you. One moment for our next question. And our next question comes from Stephanie Davis of Barclays.
Adam Schechter: Good morning, Stephanie.
Stephanie Davis: Hi guys. Good morning. Thanks for taking my question.
Stephanie Davis: I feel bad about early development because, I said we’re all focusing on this as a really small part of your business. But I have to ask because you did talk about some risk of potential share shifts when I saw you in March. So I think about the cut, is this more a function of higher for longer environment that could be impacting biotech funding? Is it something defensive early on, just in case maybe there are some potential share shifts? And how do we think about the underlying assumptions in terms of how they may have changed in use on cancellations and biotech funding in order to kind of enter new numbers.
Adam Schechter: Yes, so as I think about the early development business, I don’t think that it’s a share shifting. I think our share is remaining consistent within the parts of the market that we compete, we don’t compete in all aspects of our — we don’t have a contract manufacturing organization, for example. But in the areas that we compete — our win rates look good, our RFPs look good. So I believe that our market share is being maintained. I think we’re seeing more that there’s still a higher level of cancellations than what we’ve seen in the past. And in some instances, it’s taking a bit longer for the companies to make their final decisions because they’re still managing what I would say is a rather restricted budget even with the funding being better than it has been before.
So the good news is central laboratory, which is by far the largest part of that business remains very strong and we continue to expect it to be strong, and it’s offsetting the weakness that we continue to see in ED that could go on for a bit longer. But even if it does, we feel that the strength that we’re seeing in the largest part of the business offsets that.
Stephanie Davis: Super helpful. Thank you.
Adam Schechter: Sure.
Operator: Thank you. I’d now like to turn it back to Adam Schechter, for closing remarks.
Adam Schechter: I want to thank you all for joining us today. And hopefully, you can see we continue to advance our strategy and make significant progress. And we’re going to continue our mission to improve health and improve lives around the world. Hope, everybody has a good day.
Operator: This concludes today’s conference call. Thank you for participating. And you may now disconnect.
